Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of HB0034 in Patients Acute Generalized Pustular Psoriasis (GPP) Flare
Latest Information Update: 29 Jan 2024
Price :
$35 *
At a glance
- Drugs HB 0034 (Primary)
- Indications Generalised pustular psoriasis
- Focus Adverse reactions
- Sponsors Huaota Biopharmaceuticals
- 21 Jan 2024 Status changed from recruiting to completed.
- 09 Nov 2022 Planned primary completion date changed from 30 Oct 2022 to 30 Oct 2023.
- 09 Nov 2022 Status changed from not yet recruiting to recruiting.